Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer

Int J Biol Markers. 2013 Sep 27;28(3):326-8. doi: 10.5301/jbm.5000019.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Docetaxel
  • Humans
  • Kallikreins / blood*
  • Male
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms, Castration-Resistant / blood*
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Randomized Controlled Trials as Topic
  • Taxoids / administration & dosage

Substances

  • Taxoids
  • Docetaxel
  • KLK3 protein, human
  • Kallikreins
  • Prostate-Specific Antigen